A Phase 1b/2 Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination with Nivolumab in Patients with an Advanced Metastatic Solid Tumor | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1b/2 Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination with Nivolumab in Patients with an Advanced Metastatic Solid Tumor

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Gynecologic Cancer
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

To be considered for this trial the following cafeterias must be met: 1) Advanced/metastatic solid tumor (including ovary, uterine and cervix). 2) Advanced, recurrent, or metastatic gynecological solid tumor (Phase 2) 3) Women of childbearing potential must have a negative serum pregnancy test

You may not be eligible for this study if the following are true:

You will not be eligible for this trial if you have the following: 1) Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis 2) Known history of HIV or AIDs; positive result of hepatitis B or C viruses 3) Active second malignancy 4) Active central nervous system brain metastases 5) Pre-existing duodenal stent or any gastrointestinal disorder